Horizon Discovery Group plc is a diagnostics & research business based in the UK. Horizon Discovery Group shares (HZD.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 187p – a decrease of 0.27% over the previous week. Horizon Discovery Group employs 416 staff and has a trailing 12-month revenue of around £54.6 million.
Since the stock market crash in March caused by coronavirus, Horizon Discovery Group's share price has had significant positive movement.
Its last market close was 187p, which is 11.66% up on its pre-crash value of 165.2p and 92.58% up on the lowest point reached during the March crash when the shares fell as low as 97.1p.
If you had bought £1,000 worth of Horizon Discovery Group shares at the start of February 2020, those shares would have been worth £625.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,168.75.
|Latest market close||187p|
|52-week range||5.34p - 200p|
|50-day moving average||187.803p|
|200-day moving average||123.3092p|
|Wall St. target price||226.57p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-22.3p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-14)||3,303.09%|
|1 month (2020-12-22)||3,085.69%|
|3 months (2020-10-22)||107.78%|
|6 months (2020-07-21)||73.95%|
|1 year (2020-01-21)||25.67%|
|2 years (2019-01-21)||13.33%|
|3 years (2018-01-19)||-20.76%|
|5 years (2016-01-21)||42.75%|
Valuing Horizon Discovery Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Horizon Discovery Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Horizon Discovery Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £413,000.
The EBITDA is a measure of a Horizon Discovery Group's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£54.6 million|
|Gross profit TTM||£40.8 million|
|Return on assets TTM||-6.43%|
|Return on equity TTM||-10.32%|
|Market capitalisation||£303 million|
TTM: trailing 12 months
We're not expecting Horizon Discovery Group to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Horizon Discovery Group's shares have ranged in value from as little as 5.34p up to 200p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Horizon Discovery Group's is 2.3798. This would suggest that Horizon Discovery Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.